HK Stock Market Move | PATEO (02889) early trading surged nearly 30%, planning to conduct share repurchase in the market with a maximum of 10% of H shares.
Botech Holdings (02889) surged nearly 30% in the morning session, with an increase of 11% at the time of writing, reaching HK$111. Trading volume was HK$28.675 million.
PATEO (02889) surged nearly 30% in the morning session, rising 11% as of the press release to 111 Hong Kong dollars, with a trading volume of 28.675 million Hong Kong dollars.
On the news front, PATEO announced that a special resolution granting the board authority to repurchase shares was approved at the extraordinary general meeting of shareholders. According to the repurchase authorization, the company is allowed to repurchase up to 10% of the total number of H shares issued, which is approximately 7.1 million H shares. The company plans to repurchase its H shares on the open market from time to time. The company stated that this move aims to promote sustainable operation and development, protect the long-term interests of investors, and maximize shareholder value.
Public information shows that PATEO is one of the few top technology companies in China with "software + hardware + cloud" full-stack capabilities. As the company increases its AI layout, it is gradually surpassing the position of traditional hardware integration suppliers and evolving into an intelligent automotive application service provider with AI capabilities at its core. It is worth noting that PATEO was recently included in the Stock Connect program, and the new list took effect on March 9th.
Related Articles

Throughout the year, ZIBUYU (02420) has continued to achieve record highs in performance, unleashing strong growth potential through "brand building."

HK Stock Market Move | CSTONE PHARMA-B(02616) surged by more than 20%, CS2009 lung cancer efficacy data impressive, may initiate first phase III MRCT this year.

HK Stock Market Move | CHOW SANG SANG (00116) rose more than 5%, with net profit for the year increasing by 1.1 times compared to last year. The company will distribute a second interim dividend of 79 Hong Kong cents.
Throughout the year, ZIBUYU (02420) has continued to achieve record highs in performance, unleashing strong growth potential through "brand building."

HK Stock Market Move | CSTONE PHARMA-B(02616) surged by more than 20%, CS2009 lung cancer efficacy data impressive, may initiate first phase III MRCT this year.

HK Stock Market Move | CHOW SANG SANG (00116) rose more than 5%, with net profit for the year increasing by 1.1 times compared to last year. The company will distribute a second interim dividend of 79 Hong Kong cents.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


